Supply Chain Developments
More companies and research institutions are entering the radiopharmaceutical field. For instance, other firms are developing their own PSMA-targeted therapies or alternative isotopes. This competition can boost the overall supply.
Companies are addressing shortages by building more manufacturing facilities. Having multiple factories spreads out the risk, and increases output. International agencies and health organizations are working together to strengthen the radioisotope supply chain. Workshops hosted by groups like the OECD Nuclear Energy Agency bring experts together to find ways to prevent shortages. Similarly, the International Atomic Energy Agency, IAEA, has programs to help countries produce and transport isotopes more reliably so that shipment delays and denials are minimized. More companies and research institutions are entering the radiopharmaceutical field. For instance, other firms are developing their own PSMA-targeted therapies or alternative isotopes. This competition can boost overall supply. If one source has an issue, another source might fill the gap. Experts have noted that having multiple suppliers will make shortages less likely in the future. Clinics and manufacturers are improving how they schedule and deliver doses. They use sophisticated software to track shipments and predict decay, ensuring the patient gets an effective dose on time. Some practices include scheduling patients flexibly in case a dose comes a day late or arranging backup doses. If a delay happens, doctors quickly inform patients and adjust treatment plans to minimize health impacts. In some cases, regulators can act faster during a shortage. For example, if a drug is in short supply, authorities might allow importation from other regions or grant emergency use of an alternative product. While this is rare and situation-dependent, it’s a tool to ensure patients aren’t left without treatment. The overall trend is that stakeholders, companies, regulators, and healthcare providers are learning from early challenges and building a more resilient supply chain for these life-saving therapies.
